Iprex HFA Inhaler

Indications

Ipratropium inhaler is indicated for-

• As bronchodilator in treatment of chronic reversible airway obstruction as in asthma and Chronic Obstructive Pulmonary Disease (COPD) including chronic bronchitis and emphysema.
• Treatment of acute reversible airways obstruction.

Pharmacology

Ipratropium bromide causes bronchodilation by blocking the activity of acetylcholine at parasympathetic location in bronchial smooth muscle. It moreover hinders serous and seromucous organ discharges by nasal application.

Dosage & Administration

Adults: The usual dose is 1-2 puffs (20 µg/puff) three or four times daily. Single-dose up to 80 µg (4 puffs) may be required to obtain maximum benefit during early treatment. Patients may take additional inhalations as required: however, the total number of inhalations should not exceed 12 puffs in 24 hours.

Children:

• 6-12 years: Usually 1-2 puffs two to three times daily.
• Bellow 6 years: The usual dose is 1 puff (20 µg) three times daily.

In order to ensure that the inhaler is used correctly, the administration should be supervised by an adult.

No specific information on the use of the product in the elderly is available. Clinical trials have included patients over 65 years and no adverse reactions specific to this age group have been reported.

Following simple steps can help to use Inhaler effectively (According to “National Asthma Guidelines for Medical Practitioners” published by Asthma Association):

• Take off the cap.
• Shake the inhaler (at least six times) vigorously before each use.
• If the inhaler is new or if it has not been used for a week or more, shake it well and release one puff into the air to make sure that it works.
• Breathe out as full as comfortably possible & hold the inhaler upright.
• Place the actuator into mouth between the teeth and close lips around the mouthpiece.
• While breathing deeply and slowly through the mouth, press down firmly add fully on the canister to release medicine.
• Remove the inhaler from mouth. Continue holding breath for at least for 10 seconds or as long as it is comfortable.
• If doctor has prescribed more than one inhalation per treatment, wait 1 minute between puffs (inhalations). Shake the inhaler well and repeat steps 4 to 7.
• After use, replace the cap on the mouthpiece. After each treatment, rinse mouth with water.
• Check your technique in front of a mirror from time to time, if you see a white mist during the inhalation, you may not have closed your lips properly around mouthpiece, or you may not be breathing in as you press the can. This indicates failure of technique. If this happens, repeat the procedure from step 4 carefully.Instructions for Cleaning Inhaler: Clean your Inhaler at least once a week. Remove canister and rinse the plastic actuator and cap in warm water but do not put the metal canister into water. Dry the actuator and cap thoroughly and gently replace the metal canister into the actuator with a twisting motion. Put the cap on the mouthpiece.

Interaction

Ipratropium bromide has been used concomitantly with other drugs, including sympathomimetic bronchodilators, methylxanthines, steroids and cromolyn sodium, commonly used in treatment of COPD, without any adverse drug reactions, there are no studies fully evaluating the interaction effects of lpratropium bromide and these drugs in respect to effectiveness.

Contraindications

Known hypersensitivity to ipratropium bromide, Atropine or its derivative. Also contraindicated in patients with a history of hypersensitivity to soya lecithin or related food products such as soyabean, lecithin and peanut.

Side Effects

Quirky responses to lpratropium bromide are uncommon. Extreme unfavorable impacts due to restraint of muscarinic receptors and ganglion bar are hypothetically conceivable but improbable with the metered-dose vaporized. Customary utilize of ipratropium can lead to a dry mouth through hindrance of salivary flow. Other most common antagonistic responses detailed are – dryness of the oropharynx (5%); hack, compounding of side effects, & impersonation from airborne (3%); migraine (2%); sickness, tipsiness, obscured vision/difficulty in settlement & drying of emissions (1%).

Pregnancy & Lactation

The safety of Ipratropium Bromide during human pregnancy has not been established. The benefits of using Ipratropium Bromide during a confirmed or suspected pregnancy must be weighed against possible hazards to the unborn child. It is not known whether Ipratropium Bromide is excreted into breast milk.

Precautions & Warnings

Patients ought to be exhorted that transitory obscuring of vision, precipitation or compounding of contract point glaucoma or eye torment may result in the event that the vaporized is showered into the eyes. In the event that suggested dose does not give alleviation or side effects gotten to be more awful, patients ought to look for prompt therapeutic consideration. Whereas taking ipratropium bromide inward breath vaporized, other breathed in drugs ought to not be utilized unless prescribed.lpratropium bromide inward breath airborne isn’t shown for the introductory treatment of intense scenes of bronchospasm where fast reaction is required. Drugs with speedier onset may be ideal as beginning treatment in this circumstance. Prompt extreme touchiness responses may happen after organization of ipratropium bromide, as illustrated by uncommon cases of urticaria, angio-oedema, hasty, bronchospasm and oropharyngeal oedema.

Therapeutic Class

Anticholinergic bronchodilators

Storage Conditions

Store below 30° C in a cold, dry, and light-protected location. Keep out of children’s reach.